Drug-Related Side Effects and Adverse Reactions - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

RGD DISEASE ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:	Drug-Related Side Effects and Adverse Reactions	go back to main search page
Accession:	DOID:9006810	browse the term
Definition:	Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Synonyms:	exact_synonym:	Adverse Drug Reaction; Adverse Drug Reactions; Drug Side Effect; Drug Side Effects; Drug Toxicities; adverse drug event; adverse drug events; drug toxicity; side effects of drugs
	narrow_synonym:	antidepressant-induced dizziness
	related_synonym:	Brain pseudoatrophy, reversible, valproate-induced, susceptibility to
	primary_id:	MESH:D064420
	xref:	EFO:0006321; EFO:0020003

show annotations for term's descendants Sort by:
Rat (665) Mouse (680) Human (1272) Chinchilla (514) Bonobo (562) Dog (631) Squirrel (519) Pig (610) Green Monkey (554) Naked Mole-rat (515) All
Genes (661) QTL (1) Strains (3)

Drug-Related Side Effects and Adverse Reactions

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

CTD Direct Evidence: marker/mechanism

PMID:18381794 PMID:20563569 PMID:21064136 PMID:24502637 PMID:25007187 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 12

CTD Direct Evidence: marker/mechanism

NCBI chr19:20,549,298...20,621,991
Ensembl chr19:20,549,405...20,620,734

G

ATP binding cassette subfamily C member 2

CTD Direct Evidence: marker/mechanism

PMID:20216337 PMID:23222202 PMID:25007187 PMID:32387182

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 4

CTD Direct Evidence: marker/mechanism

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily G member 2

CTD Direct Evidence: marker/mechanism

PMID:21064136 PMID:32387182

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acetylcholinesterase

CTD Direct Evidence: therapeutic

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

adenosine A1 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adenosine A2a receptor

CTD Direct Evidence: marker/mechanism

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

afamin

CTD Direct Evidence: marker/mechanism

NCBI chr14:17,531,022...17,563,868
Ensembl chr14:17,531,024...17,563,870

G

alpha-2-HS-glycoprotein

CTD Direct Evidence: marker/mechanism

NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999

G

albumin

CTD Direct Evidence: marker/mechanism

PMID:24361871 PMID:28885000

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alpha-1-microglobulin/bikunin precursor

CTD Direct Evidence: marker/mechanism

NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331

G

apolipoprotein B

CTD Direct Evidence: marker/mechanism

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

AT-rich interaction domain 5B

CTD Direct Evidence: marker/mechanism

NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433

G

argininosuccinate synthase 1

protein:increased expression:plasma (rat)

RGD

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

CTD Direct Evidence: marker/mechanism

NCBI chr 9:73,164,846...73,184,897
Ensembl chr 9:73,164,846...73,184,889

G

beta-2 microglobulin

CTD Direct Evidence: marker/mechanism

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

butyrylcholinesterase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

complement C3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

calcium voltage-gated channel subunit alpha1 H

CTD Direct Evidence: marker/mechanism

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

associated with colon cancer

RGD

NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600

G

C-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

cytidine deaminase

DNA:SNP:cds:rs1048977|rs12726436|rs2072671 (human)

RGD

NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231

G

carboxylesterase 2H

CTD Direct Evidence: marker/mechanism

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

clusterin

CTD Direct Evidence: marker/mechanism

PMID:24361871 PMID:28885000

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

copper metabolism domain containing 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501

G

ceruloplasmin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

colony stimulating factor 2

CTD Direct Evidence: therapeutic

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 3

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:7692001 PMID:27737899 PMID:31557154

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

cystatin C

CTD Direct Evidence: marker/mechanism

NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822

G

cytochrome P450, family 1, subfamily a, polypeptide 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily c, polypeptide 79

CTD Direct Evidence: marker/mechanism

G

cytochrome P450, family 2, subfamily d, polypeptide 4

CTD Direct Evidence: marker/mechanism

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

dihydrofolate reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

disco-interacting protein 2 homolog B

CTD Direct Evidence: marker/mechanism

NCBI chr 7:131,174,575...131,350,417
Ensembl chr 7:131,174,567...131,349,092

G

dihydropyrimidine dehydrogenase

DNA:SNP:cds:rs12119882 (human)

RGD

NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982

G

enolase superfamily member 1

DNA:SNP:cds:rs699517 (human)

RGD

NCBI chr 9:113,275,267...113,314,842

G

Eph receptor A7

CTD Direct Evidence: marker/mechanism

NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112

G

epoxide hydrolase 2

CTD Direct Evidence: therapeutic

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

ERCC excision repair 1, endonuclease non-catalytic subunit

treatment

associated with Breast Neoplasms;DNA:SNP: :p.Q504K (human)
associated with Leukemia, Myeloid, Acute

RGD

PMID:25495407 PMID:17197435

RGD:11252168, RGD:11252178

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 2, TFIIH core complex helicase subunit

treatment

DNA:SNP: :p.K751Q (rs13181) (human)
associated with Leukemia, Myeloid, Acute;DNA:SNPs, haplotypes: :p.D312N, p.K751Q (human)

RGD

PMID:15339847 PMID:17197435

RGD:11252202, RGD:11252178

NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102

G

fibrinogen alpha chain

CTD Direct Evidence: marker/mechanism

NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528

G

fibronectin type III domain containing 3B

CTD Direct Evidence: marker/mechanism

NCBI chr 2:110,311,439...110,617,504
Ensembl chr 2:110,312,694...110,547,830

G

GATA binding protein 4

CTD Direct Evidence: marker/mechanism

NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636

G

GATA binding protein 6

CTD Direct Evidence: marker/mechanism

NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532

G

GC, vitamin D binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567

G

glutathione S-transferase alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

hepatitis A virus cellular receptor 1

CTD Direct Evidence: marker/mechanism

PMID:15805072 PMID:24361871 PMID:28885000

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

high mobility group box 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homer scaffold protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

haptoglobin

CTD Direct Evidence: marker/mechanism

NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523

G

hemopexin

CTD Direct Evidence: marker/mechanism

NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328

G

heat shock protein family B (small) member 6

CTD Direct Evidence: therapeutic

NCBI chr 1:85,806,898...85,809,072
Ensembl chr 1:85,806,146...85,809,071

G

5-hydroxytryptamine receptor 2B

CTD Direct Evidence: marker/mechanism

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

G

interferon gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

CTD Direct Evidence: therapeutic

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

gamma-2a immunoglobulin heavy chain

CTD Direct Evidence: marker/mechanism

G

interleukin 10

CTD Direct Evidence: marker/mechanism

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 receptor antagonist

CTD Direct Evidence: marker/mechanism

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 3

CTD Direct Evidence: therapeutic

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 6

CTD Direct Evidence: marker/mechanism

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

KIT ligand

CTD Direct Evidence: therapeutic

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

lipocalin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

lymphotoxin beta receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:158,108,884...158,115,339
Ensembl chr 4:158,108,886...158,121,539

G

mitogen activated protein kinase 14

susceptibility

associated with lung non-small cell carcinoma;DNA:SNP:3' utr, intron: (rs3804451) (human)

RGD

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

molybdenum cofactor sulfurase

CTD Direct Evidence: marker/mechanism

NCBI chr18:15,931,659...15,977,415
Ensembl chr18:15,931,654...15,977,187

G

mitochondrially encoded ATP synthase membrane subunit 8

ClinVar Annotator: match by term: Brain pseudoatrophy, reversible, valproate-induced, susceptibility to

PMID:9243242 PMID:17101920

NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
NCBI chr MT:7,758...7,961
Ensembl chr MT:7,758...7,961

G

methylenetetrahydrofolate reductase

CTD Direct Evidence: marker/mechanism

PMID:15753437 PMID:16166815 PMID:17387702 PMID:17502830 PMID:18551038 More...

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

5-methyltetrahydrofolate-homocysteine methyltransferase

CTD Direct Evidence: marker/mechanism

PMID:15753437 PMID:19159907

NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822

G

5-methyltetrahydrofolate-homocysteine methyltransferase reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:34,866,991...34,899,425
Ensembl chr 1:34,867,089...34,899,425

G

murinoglobulin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051

G

N-acetyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520

G

N-acetyltransferase 2

susceptibility

DNA:polymorphism: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:17377643 PMID:17502830 PMID:12786839

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

NFE2 like bZIP transcription factor 2

CTD Direct Evidence: therapeutic

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear receptor subfamily 3, group C, member 1

CTD Direct Evidence: marker/mechanism

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

5'-nucleotidase, cytosolic II

CTD Direct Evidence: marker/mechanism

NCBI chr 1:245,770,993...245,896,925
Ensembl chr 1:245,772,277...245,897,913

G

orosomucoid 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

pellino E3 ubiquitin protein ligase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:95,254,274...95,309,168
Ensembl chr14:95,254,589...95,308,285
Ensembl chr 1:95,254,589...95,308,285

G

plasminogen

CTD Direct Evidence: marker/mechanism

NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786

G

polo-like kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

peroxisome proliferator activated receptor alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

renin

CTD Direct Evidence: marker/mechanism

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

urinary protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:35,336,764...35,340,345
Ensembl chr 8:35,336,764...35,489,103

G

serpin family A member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339

G

serine hydroxymethyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:45,468,698...45,490,833
Ensembl chr10:45,468,700...45,497,820

G

solute carrier family 19 member 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972

G

solute carrier family 22 member 7

DNA:SNP:cds:rs2270860|rs4149178 (human)

RGD

NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921

G

solute carrier family 34 member 2

CTD Direct Evidence: marker/mechanism

NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436

G

solute carrier organic anion transporter family, member 2a1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:103,588,916...103,672,546
Ensembl chr 8:103,588,916...103,672,546

G

superoxide dismutase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

secreted phosphoprotein 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

transcobalamin 2

CTD Direct Evidence: marker/mechanism

NCBI chr14:78,813,343...78,828,549
Ensembl chr14:78,813,343...78,828,489

G

transferrin

CTD Direct Evidence: marker/mechanism

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

thrombomodulin

CTD Direct Evidence: therapeutic

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

toll-like receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125

G

toll-like receptor 2

CTD Direct Evidence: marker/mechanism

PMID:18466103 PMID:31557154

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

DNA topoisomerase I

CTD Direct Evidence: marker/mechanism

NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623

G

tumor protein p53

CTD Direct Evidence: marker/mechanism

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

transthyretin

CTD Direct Evidence: marker/mechanism

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008

G

thioredoxin 1

CTD Direct Evidence: therapeutic

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thymidylate synthetase

CTD Direct Evidence: marker/mechanism
DNA:SNP:cds:rs2853741 (human)

CTD
RGD

PMID:19648163 PMID:21064136 PMID:25007187 PMID:26077125 PMID:28347776

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

UDP glucuronosyltransferase family 1 member A1

CTD Direct Evidence: therapeutic

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

uridine monophosphate synthetase

DNA:SNP:cds:rs2279199|rs4678145 (human)

RGD

NCBI chr11:66,806,107...66,816,520
Ensembl chr11:66,806,045...66,821,903

G

vascular endothelial growth factor A

CTD Direct Evidence: marker/mechanism

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vitamin K epoxide reductase complex, subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008

Anthracycline-induced Cardiotoxicity

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

susceptibility

DNA:missense mutation:cds:p.G671V (human)

RGD

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

activin A receptor type 2B

treatment

human construct in mouse model

RGD

NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458

G

calpain 2

treatment

RGD

NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969

G

ERCC excision repair 2, TFIIH core complex helicase subunit

associated with Leukemia, Myeloid, Acute;DNA:SNP:exon:p.K751Q (rs13181) (human)

RGD

NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102

aspirin-induced respiratory disease

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcium voltage-gated channel auxiliary subunit gamma 6

susceptibility

DNA:SNP,haplotype:rs192808(human)

RGD

NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341

G

C-C motif chemokine receptor 3

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20485159 PMID:20022477

NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990

G

cysteinyl leukotriene receptor 1

CTD Direct Evidence: marker/mechanism

PMID:16502481 PMID:17641958 PMID:20485159

NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121

G

cysteinyl leukotriene receptor 2

DNA:SNPs: :-819T>G, 2078C>T, 2534A>G (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:15970796

NCBI chr15:48,189,476...48,228,750
Ensembl chr15:48,189,073...48,304,136

G

FA complementation group C

DNA:haplotype::rs4647416(human)

RGD

NCBI chr17:1,680,660...1,822,610
Ensembl chr17:1,681,324...1,829,376

G

interleukin 4

susceptibility

DNA:SNPs:promoter,5'UTR,intron:multiple

RGD

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

leukotriene C4 synthase

CTD Direct Evidence: marker/mechanism

PMID:9393345 PMID:9466979 PMID:10970818 PMID:20485159

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

membrane spanning 4-domains A2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:208,440,179...208,448,716
Ensembl chr 1:208,440,361...208,448,310

G

periostin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099

G

prostaglandin D2 receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213

G

prostaglandin E receptor 2

ClinVar Annotator: match by term: Asthma, aspirin-induced, susceptibility to
CTD Direct Evidence: marker/mechanism

PMID:15496426 PMID:16502481

NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714

G

prostaglandin I2 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:77,579,596...77,581,979

G

prostaglandin-endoperoxide synthase 2

protein:increased expression:mast cell
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:9487340

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RT1 class II, locus Ba

susceptibility

RGD

NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744

G

RT1 class II, locus Bb

susceptibility

RGD

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class II, locus Db1

susceptibility

RGD

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

G

RT1 class II, locus Hb, pseudogene 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618

G

transporter 2, ATP binding cassette subfamily B member

RGD

NCBI chr20:4,636,347...4,650,387
Ensembl chr20:4,636,357...4,650,407

G

T-box transcription factor 21

ClinVar Annotator: match by term: Asthma, aspirin-induced, susceptibility to
CTD Direct Evidence: marker/mechanism

PMID:15806396 PMID:16502481

NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831

G

thromboxane A2 receptor

susceptibility

DNA:polymorphism: :795T>C (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:15898979

NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176

asthma, nasal polyps, and aspirin intolerance

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 15-lipoxygenase

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance

PMID:17959182 PMID:21558275 PMID:25741868 PMID:30643255

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

leukotriene C4 synthase

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

prostaglandin E receptor 2

susceptibility

CTD Direct Evidence: marker/mechanism

NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714

G

T-box transcription factor 21

susceptibility

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance
CTD Direct Evidence: marker/mechanism

ClinVar
OMIM
CTD

NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831

Cardiotoxicity

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase beta

mRNA, protein:increased expression:heart (rat)

RGD

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

angiotensinogen

CTD Direct Evidence: marker/mechanism

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

butyrylcholinesterase

CTD Direct Evidence: therapeutic

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

bone morphogenetic protein 2

CTD Direct Evidence: therapeutic

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

catalase

CTD Direct Evidence: therapeutic

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

carnitine palmitoyltransferase 1A

mRNA, protein:decreased expression:heart (rat)

RGD

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

colony stimulating factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

Fas cell surface death receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

CTD Direct Evidence: marker/mechanism

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

FTO, alpha-ketoglutarate dependent dioxygenase

DNA:hypermethylation:promoter

RGD

NCBI chr19:15,284,898...15,692,142
Ensembl chr19:15,349,696...15,692,083

G

heparin-binding EGF-like growth factor

CTD Direct Evidence: therapeutic

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

potassium calcium-activated channel subfamily N member 2

CTD Direct Evidence: therapeutic

PMID:32909839 PMID:33887967

NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347

G

methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 2:211,530,598...211,546,845
Ensembl chr 2:211,530,602...211,546,821

G

microRNA 143

ameliorates

RGD

NCBI chr18:55,101,006...55,101,110
Ensembl chr18:55,101,006...55,101,110

G

microRNA 208a

CTD Direct Evidence: marker/mechanism

NCBI chr15:28,425,570...28,425,652

G

malonyl-CoA decarboxylase

protein:increased expression:heart (rat)

RGD

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

nitric oxide synthase 3

treatment

associated with Precursor Cell Lymphoblastic Leukemia-Lymphoma;DNA:polymorphism: :894G>T(human)

RGD

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

natriuretic peptide B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

neuregulin 1

CTD Direct Evidence: therapeutic

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

protein kinase AMP-activated catalytic subunit alpha 2

protein:decreased expression:serum, heart (rat)

RGD

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

G

Rac family small GTPase 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

retinoic acid receptor, gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177

G

ring finger protein 10

CTD Direct Evidence: therapeutic

NCBI chr12:41,341,708...41,375,505
Ensembl chr12:41,341,717...41,375,504

G

sirtuin 6

CTD Direct Evidence: therapeutic

NCBI chr 7:8,082,312...8,087,776
Ensembl chr 7:8,082,364...8,098,914

G

toll-like receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

PMID:29959987 PMID:32068018

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

CTD Direct Evidence: marker/mechanism

PMID:30009776 PMID:34713381

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

Chemical and Drug Induced Liver Injury

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate-semialdehyde synthase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136

G

ATP binding cassette subfamily B member 11

severity

DNA:SNP: :rs2287616(human)

RGD

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

severity
susceptibility

DNA:SNP::2677G>T/A(rs2032582)(human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20623750 PMID:26134275 PMID:26134275 PMID:27296832

RGD:11041130, RGD:14700895

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

CTD Direct Evidence: marker/mechanism

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily C member 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

susceptibility

CTD Direct Evidence: marker/mechanism
DNA:polymorphism:promoter:-24C>T(human)

CTD
RGD

PMID:18381794 PMID:18466103 PMID:17241877 PMID:25196354

RGD:14700814, RGD:14700812

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

abl-interactor 1

CTD Direct Evidence: marker/mechanism

NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792

G

angiotensin I converting enzyme

mRNA:increased expression:liver (rat)

RGD

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acyl-CoA oxidase 3, pristanoyl

CTD Direct Evidence: marker/mechanism

NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205

G

acyl-CoA synthetase long-chain family member 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

actin, beta

mRNA:increased expression:liver
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:25231249 PMID:22563491

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

actinin alpha 4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847

G

actin related protein 3

CTD Direct Evidence: marker/mechanism

NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124

G

adenosine deaminase

protein:increased expression:liver

RGD

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

ADAM metallopeptidase domain 8

CTD Direct Evidence: marker/mechanism

NCBI chr 1:194,776,559...194,789,330
Ensembl chr 1:194,770,060...194,788,801

G

adiponectin, C1Q and collagen domain containing

CTD Direct Evidence: therapeutic

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adiponectin receptor 2

severity

associated with obesity, LPS;mRNA:decreased expression:liver (rat)

RGD

NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355

G

adenosine A2B receptor

CTD Direct Evidence: therapeutic

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

angiotensinogen

CTD Direct Evidence: marker/mechanism

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aryl hydrocarbon receptor

CTD Direct Evidence: marker/mechanism|therapeutic
mRNA:decreased expression:liver (rat)

CTD
RGD

PMID:21890736 PMID:34848246 PMID:28959666

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

adenylate kinase 4

protein:increased expression:liver (rat)

RGD

NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618

G

aldo-keto reductase family 1 member A1

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:32805337 PMID:29763686

NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674

G

albumin

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:18779383 PMID:22310181 PMID:27567545

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member L2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776

G

aldehyde dehydrogenase 2 family member

severity
susceptibility

protein:increased expression:liver
DNA:deletion:exon 3 (mouse)

RGD

PMID:21138988 PMID:30121625 PMID:24492981

RGD:7241599, RGD:15036810, RGD:14975148

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 9 family, member A1

CTD Direct Evidence: marker/mechanism

NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568

G

aldolase, fructose-bisphosphate B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116

G

alpha-1-microglobulin/bikunin precursor

CTD Direct Evidence: marker/mechanism

NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331

G

annexin A2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

annexin A6

CTD Direct Evidence: marker/mechanism

NCBI chr10:39,101,395...39,156,483
Ensembl chr10:39,097,109...39,156,433

G

apolipoprotein A1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein E

CTD Direct Evidence: marker/mechanism

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein H

mRNA:increased expression:plasma:
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16099942 PMID:23288050

NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329

G

arginase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

aryl hydrocarbon receptor nuclear translocator

CTD Direct Evidence: marker/mechanism

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

autophagy related 5

CTD Direct Evidence: marker/mechanism

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

atonal bHLH transcription factor 8

CTD Direct Evidence: marker/mechanism

NCBI chr 4:104,259,992...104,292,168
Ensembl chr 4:104,259,992...104,292,168

G

ATPase H+ transporting V1 subunit D

CTD Direct Evidence: marker/mechanism

NCBI chr 6:97,656,725...97,672,295
Ensembl chr 6:97,656,576...97,672,303

G

arginine vasopressin

DNA:SNP:intron: (rs2282018)

RGD

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2-associated agonist of cell death

treatment

RGD

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

3-hydroxybutyrate dehydrogenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671

G

bradykinin receptor B2

CTD Direct Evidence: marker/mechanism

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

biliverdin reductase B

CTD Direct Evidence: marker/mechanism

NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375

G

basic helix-loop-helix ARNT like 1

CTD Direct Evidence: therapeutic

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

3'(2'), 5'-bisphosphate nucleotidase 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:96,865,634...96,893,506
Ensembl chr13:96,868,580...96,893,503

G

bromodomain containing 4

CTD Direct Evidence: marker/mechanism

NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539

G

biotinidase

CTD Direct Evidence: marker/mechanism

NCBI chr16:6,863,068...6,894,345
Ensembl chr16:6,862,407...6,940,945

G

complement C3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

calcium binding protein 1

protein:increased expression:liver

RGD

NCBI chr12:41,385,234...41,448,930
Ensembl chr12:41,378,897...41,448,927

G

calcium dependent secretion activator 2

CTD Direct Evidence: marker/mechanism

NCBI chr 4:51,780,415...52,309,641
Ensembl chr 4:51,781,053...52,309,829

G

calnexin

CTD Direct Evidence: marker/mechanism

NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821

G

cyclase associated actin cytoskeleton regulatory protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769

G

carbonic anhydrase 3

CTD Direct Evidence: marker/mechanism

PMID:25226513 PMID:25231249

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

caspase 8

treatment

RGD

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

calpastatin

RGD

NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659

G

catalase

CTD Direct Evidence: marker/mechanism
protein:decreased expression:liver

CTD
RGD

PMID:20623750 PMID:25231249 PMID:21138988

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 80

CTD Direct Evidence: marker/mechanism

NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137

G

C-C motif chemokine ligand 2

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20623750 PMID:21813474 PMID:30663942

RGD:14995466, RGD:14995458

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 5

susceptibility

acetaminophen

RGD

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

chaperonin containing TCP1 subunit 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:173,765,701...173,790,353
Ensembl chr 2:173,765,698...173,790,757

G

chaperonin containing TCP1 subunit 5

CTD Direct Evidence: marker/mechanism

NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930

G

cell division cycle 25B

CTD Direct Evidence: marker/mechanism

NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272

G

CDP-diacylglycerol synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

chymotrypsin like elastase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:131,773,161...131,786,300
Ensembl chr 7:131,742,002...131,786,285

G

cilia and flagella associated protein 20

CTD Direct Evidence: marker/mechanism

NCBI chr19:9,608,867...9,622,558
Ensembl chr19:9,608,859...9,622,558

G

complement factor H

CTD Direct Evidence: marker/mechanism

NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838

G

cholinergic receptor, muscarinic 3

CTD Direct Evidence: marker/mechanism

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

G

creatine kinase B

CTD Direct Evidence: marker/mechanism

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

clusterin

CTD Direct Evidence: marker/mechanism

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

collagen type XIV alpha 1 chain

CTD Direct Evidence: marker/mechanism

NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214

G

collagen type III alpha 1 chain

CTD Direct Evidence: marker/mechanism

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

catechol-O-methyltransferase

protein:decreased expression:liver

RGD

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

coenzyme Q9

CTD Direct Evidence: marker/mechanism

NCBI chr19:10,166,948...10,179,976
Ensembl chr19:10,166,951...10,179,949

G

ceruloplasmin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

carboxypeptidase B2

mRNA,protein:increased expression,increased activity:liver,plasma

RGD

NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556

G

carbamoyl-phosphate synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033

G

carnitine palmitoyltransferase 1A

mRNA:decreased expression:liver (rat)

RGD

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

C-reactive protein

CTD Direct Evidence: marker/mechanism

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

colony stimulating factor 3

CTD Direct Evidence: therapeutic

PMID:20005281 PMID:33882750

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

catenin beta 1

CTD Direct Evidence: therapeutic

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin E

CTD Direct Evidence: marker/mechanism

NCBI chr13:43,091,954...43,114,509
Ensembl chr13:43,092,128...43,114,502

G

C-X-C motif chemokine ligand 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

CTD Direct Evidence: therapeutic

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 14

CTD Direct Evidence: marker/mechanism

NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839

G

C-X-C motif chemokine ligand 3

CTD Direct Evidence: marker/mechanism

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

cytochrome P450, family 1, subfamily a, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 27, subfamily b, polypeptide 1

mRNA, protein:decreased expression:kidney (mouse)

RGD

NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241

G

cytochrome P450, family 2, subfamily b, polypeptide 3

CTD Direct Evidence: marker/mechanism

PMID:28762043 PMID:33814510

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

CTD Direct Evidence: marker/mechanism

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

CTD Direct Evidence: marker/mechanism

PMID:12963435 PMID:28762043

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

DNA:hypermethylation:promoter

RGD

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

treatment

CTD Direct Evidence: marker/mechanism
DNA:hypermethylation:promoter
associated with Endotoxemia

CTD
RGD

PMID:12668988 PMID:16770646 PMID:21741958 PMID:28762043 PMID:27960551 More...

RGD:14700901, RGD:14700879, RGD:14700878, RGD:14700873, RGD:14700872

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

CTD Direct Evidence: marker/mechanism

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 4, subfamily a, polypeptide 3

CTD Direct Evidence: marker/mechanism

NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463

G

cytochrome P450 family 8 subfamily B member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

dihydrolipoamide branched chain transacylase E2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609

G

damage-specific DNA binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:207,252,890...207,278,685
Ensembl chr 1:207,252,890...207,278,676

G

diacylglycerol O-acyltransferase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428

G

dihydrofolate reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

dehydrogenase/reductase 7

CTD Direct Evidence: marker/mechanism

NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892

G

dihydrolipoamide S-acetyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
Ensembl chr 1:50,978,051...51,004,479

G

DnaJ heat shock protein family (Hsp40) member B9

CTD Direct Evidence: marker/mechanism

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C12

CTD Direct Evidence: marker/mechanism

NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521

G

desmocollin 2

CTD Direct Evidence: marker/mechanism

NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392

G

E2F transcription factor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

ethylmalonyl-CoA decarboxylase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:28,476,354...28,507,173
Ensembl chr 1:28,476,200...28,507,319

G

enoyl-CoA hydratase, short chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884

G

ER degradation enhancing alpha-mannosidase like protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717

G

eukaryotic translation initiation factor 2 alpha kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:10,710,771...10,744,597
Ensembl chr12:10,705,874...10,744,573

G

eukaryotic translation initiation factor 4E binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr20:29,379,444...29,400,110
Ensembl chr20:29,382,668...29,399,946

G

endonuclease G

protein:decreased expression:mitochondrion:

RGD

NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932

G

endoglin

protein:increased expression:liver (rat)

RGD

NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230

G

enolase 1

CTD Direct Evidence: marker/mechanism

PMID:16099942 PMID:25231249

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
Ensembl chr 3:160,719,951...160,731,336

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

protein:increased activity:serum:

RGD

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

epoxide hydrolase 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

endoplasmic reticulum lectin 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:104,655,745...104,693,508
Ensembl chr14:104,655,673...104,693,480

G

endoplasmic reticulum to nucleus signaling 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

coagulation factor XIII A1 chain

RGD

NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700

G

F2R like thrombin or trypsin receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472

G

coagulation factor III, tissue factor

CTD Direct Evidence: marker/mechanism

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

Fas associated via death domain

treatment

RGD

PMID:26062544 PMID:25447754

RGD:11341803, RGD:10053709

NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653

G

fatty acid desaturase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

fatty acid desaturase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas cell surface death receptor

protein:increased expression:liver (rat)

RGD

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fatty acid synthase

CTD Direct Evidence: marker/mechanism

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

Fc mu receptor

CTD Direct Evidence: marker/mechanism

NCBI chr13:42,337,363...42,351,706
Ensembl chr13:42,337,414...42,351,653

G

fibrinogen alpha chain

CTD Direct Evidence: marker/mechanism

NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528

G

fibroblast growth factor 21

severity

mRNA:increased expression:liver (rat)

RGD

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

Fms related receptor tyrosine kinase 1

CTD Direct Evidence: therapeutic

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

flavin containing dimethylaniline monoxygenase 3

CTD Direct Evidence: therapeutic

NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028

G

ferritin light chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
Ensembl chr 2:95,936,387...95,939,725

G

glucose-6-phosphatase catalytic subunit 1

mRNA:decreased expression:liver (mouse)

RGD

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glucose-6-phosphate dehydrogenase

treatment

RGD

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

growth arrest and DNA-damage-inducible, alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

glucosidase II alpha subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695

G

GC, vitamin D binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567

G

glutamate-cysteine ligase, catalytic subunit

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19481141 PMID:17573345

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

guanine deaminase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416

G

GDP dissociation inhibitor 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:152,087,611...152,094,274
Ensembl chr X:152,087,444...152,094,272

G

growth factor, augmenter of liver regeneration

treatment

RGD

PMID:22033404 PMID:15968720

RGD:9685722, RGD:9685727

NCBI chr10:13,718,489...13,721,782
Ensembl chr10:13,718,489...13,720,869

G

gamma-glutamyl hydrolase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787

G

gamma-glutamyltransferase 1

RGD

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

ghrelin and obestatin prepropeptide

CTD Direct Evidence: therapeutic

NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621

G

glutamate dehydrogenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

glutamic-oxaloacetic transaminase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glycerol-3-phosphate dehydrogenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529

G

glutamic--pyruvic transaminase

treatment

CTD Direct Evidence: marker/mechanism
protein:increased expression, activity:serum:

CTD
RGD

PMID:145039 PMID:19481104 PMID:19085960 PMID:19085960 PMID:27293452 More...

RGD:14975249, RGD:14975249, RGD:14975168, RGD:14975166, RGD:14975162

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutamic--pyruvic transaminase 2

protein:increased expression, activity:serum:

RGD

PMID:19085960 PMID:19085960

RGD:14975249, RGD:14975249

NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610

G

G protein-coupled receptor kinase 4

CTD Direct Evidence: marker/mechanism

NCBI chr14:75,998,554...76,080,808
Ensembl chr14:76,006,218...76,080,693

G

gelsolin

CTD Direct Evidence: marker/mechanism

NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402

G

glutathione-disulfide reductase

treatment

mRNA, protein:increased expression:liver
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:25226513 PMID:28069987 PMID:23554813 PMID:24154663

RGD:7257532, RGD:10401878

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 4

CTD Direct Evidence: marker/mechanism

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase mu 1

no_association

CTD Direct Evidence: marker/mechanism
protein:increased expression:liver

CTD
RGD

PMID:17465707 PMID:18666253 PMID:25501156 PMID:24465778 PMID:24903797 More...

RGD:14700970, RGD:14700959, RGD:14700941, RGD:14700937, RGD:7241599

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase mu 4

CTD Direct Evidence: marker/mechanism

NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323

G

glutathione S-transferase, mu 5

CTD Direct Evidence: therapeutic

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase omega 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468

G

glutathione S-transferase pi 1

CTD Direct Evidence: marker/mechanism

PMID:20623750 PMID:25226513

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

CTD Direct Evidence: marker/mechanism

PMID:18397238 PMID:18666253 PMID:25226513

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

H19 imprinted maternally expressed transcript

CTD Direct Evidence: marker/mechanism

NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134

G

H2A.X variant histone

treatment

RGD

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

2-hydroxyacyl-CoA lyase 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

hepcidin antimicrobial peptide

mRNA:increased expression:hepatocyte

RGD

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

hydroxyacid oxidase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:186,200,137...186,232,997
Ensembl chr 2:186,200,504...186,224,425

G

hepatitis A virus cellular receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

hemoglobin alpha, adult chain 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392

G

high mobility group box 1

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19783637 PMID:29091898

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

treatment

CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:18227147 PMID:22688006 PMID:22886620 PMID:29091898

RGD:10762620, RGD:15090820

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

4-hydroxyphenylpyruvate dioxygenase

CTD Direct Evidence: marker/mechanism

PMID:16099942 PMID:22872058

NCBI chr12:33,381,397...33,392,750
Ensembl chr12:33,381,231...33,392,766

G

hypoxanthine phosphoribosyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154

G

hemopexin

CTD Direct Evidence: marker/mechanism

NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328

G

histamine receptor H 2

CTD Direct Evidence: marker/mechanism

NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631

G

heat shock protein family A (Hsp70) member 5

CTD Direct Evidence: marker/mechanism

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

protein:altered localization:liver (rat)

RGD

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

intercellular adhesion molecule 1

treatment

RGD

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

isocitrate dehydrogenase (NADP(+)) 2

severity

RGD

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

indoleamine 2,3-dioxygenase 2

CTD Direct Evidence: marker/mechanism

NCBI chr16:67,459,158...67,498,052
Ensembl chr16:67,459,190...67,496,324

G

interferon gamma

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:12153990 PMID:21245496 PMID:30013034

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

CTD Direct Evidence: marker/mechanism

PMID:23639586 PMID:25226513

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 11

CTD Direct Evidence: therapeutic

NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129

G

interleukin 12B

CTD Direct Evidence: therapeutic

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 17A

CTD Direct Evidence: marker/mechanism

PMID:19633216 PMID:24949944

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 18

CTD Direct Evidence: marker/mechanism

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

CTD Direct Evidence: therapeutic

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

treatment

CTD Direct Evidence: marker/mechanism|therapeutic

CTD
RGD

PMID:19164858 PMID:28138970 PMID:23102243 PMID:29091898 PMID:31342809 More...

RGD:7204421, RGD:15090820, RGD:15036799, RGD:14975281, RGD:13793380

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725

G

interleukin 22

CTD Direct Evidence: therapeutic

PMID:15122762 PMID:16212920 PMID:23375450

NCBI chr 7:53,801,206...53,805,673
Ensembl chr 7:53,801,206...53,806,186

G

interleukin 4

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:21094227 PMID:21735453 PMID:22107450

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

treatment

CTD Direct Evidence: therapeutic

CTD
RGD

PMID:7532385 PMID:15763341 PMID:29091898

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inner membrane mitochondrial protein

CTD Direct Evidence: marker/mechanism

NCBI chr 4:103,880,482...103,919,116
Ensembl chr 4:103,880,459...103,919,109

G

interleukin-1 receptor-associated kinase 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

inositol 1,4,5-trisphosphate receptor, type 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

JunD proto-oncogene, AP-1 transcription factor subunit

CTD Direct Evidence: marker/mechanism

NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799

G

Kelch-like ECH-associated protein 1

RGD

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

KIT ligand

CTD Direct Evidence: therapeutic

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

kininogen 1

CTD Direct Evidence: marker/mechanism

PMID:20362651 PMID:30685357

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

keratin 18

mRNA, protein:increased expression:liver (mouse)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:19783637 PMID:33483742 PMID:38521541 PMID:17340120

NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166

G

keratin 8

CTD Direct Evidence: marker/mechanism

NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728

G

leucine aminopeptidase 3

CTD Direct Evidence: marker/mechanism

NCBI chr14:65,608,375...65,627,359
Ensembl chr14:65,608,376...65,627,359

G

lipopolysaccharide binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

lecithin cholesterol acyltransferase

mRNA:decreased expression:liver (rat)

RGD

NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231

G

lipocalin 2

CTD Direct Evidence: marker/mechanism

PMID:20362651 PMID:20623750

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

low density lipoprotein receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

galectin 3

CTD Direct Evidence: marker/mechanism

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

lipase C, hepatic type

mRNA:decreased expression:liver (rat)

RGD

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lipoprotein lipase

treatment

RGD

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

lecithin retinol acyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:168,264,093...168,273,155
Ensembl chr 2:168,266,877...168,273,619

G

leukotriene B4 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr15:29,263,199...29,265,716

G

lactotransferrin

CTD Direct Evidence: therapeutic

NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795

G

microtubule-associated protein 1 light chain 3 beta

CTD Direct Evidence: marker/mechanism

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase kinase 5

CTD Direct Evidence: marker/mechanism

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

methionine adenosyltransferase 1A

CTD Direct Evidence: marker/mechanism

NCBI chr16:16,983,084...17,001,284
Ensembl chr16:16,983,022...17,001,274

G

methylcrotonyl-CoA carboxylase subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:118,799,147...118,851,181
Ensembl chr 2:118,799,150...118,851,222

G

malate dehydrogenase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925

G

malic enzyme 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

mediator complex subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299

G

microRNA 100

CTD Direct Evidence: marker/mechanism

NCBI chr 8:41,901,225...41,901,304
Ensembl chr 8:41,901,225...41,901,304

G

microRNA 103a-1

CTD Direct Evidence: marker/mechanism

NCBI chr10:20,244,412...20,244,497
Ensembl chr10:20,244,412...20,244,497

G

microRNA 106b

miRNA:decreased expression:liver (rat)
DNA:hypermethylation:promoter

RGD

PMID:29554950 PMID:29554950

RGD:15042854, RGD:15042854

NCBI chr12:17,043,344...17,043,425
Ensembl chr12:17,043,344...17,043,425

G

microRNA 107

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr 1:232,337,767...232,337,853
Ensembl chr 1:232,337,767...232,337,853

G

microRNA 10a

CTD Direct Evidence: marker/mechanism

NCBI chr10:81,283,171...81,283,280
Ensembl chr10:81,283,171...81,283,280

G

microRNA 10b

CTD Direct Evidence: marker/mechanism

NCBI chr 3:59,628,438...59,628,546
Ensembl chr 3:59,628,438...59,628,546

G

microRNA 122

CTD Direct Evidence: marker/mechanism

PMID:22045675 PMID:22363424 PMID:25359176 PMID:25527335 PMID:26489516 More...

NCBI chr18:58,758,703...58,758,787

G

microRNA 1249

CTD Direct Evidence: marker/mechanism

NCBI chr 7:116,075,593...116,075,712
Ensembl chr 7:116,075,593...116,075,712

G

microRNA 125b-1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:41,952,966...41,953,052
Ensembl chr 8:41,952,966...41,953,052

G

microRNA 125b-2

CTD Direct Evidence: marker/mechanism

NCBI chr11:16,245,620...16,245,707

G

microRNA 1306

CTD Direct Evidence: marker/mechanism

NCBI chr11:82,709,651...82,709,723
Ensembl chr11:82,709,637...82,709,719

G

microRNA 130a

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr 3:69,822,542...69,822,629
Ensembl chr 3:69,822,542...69,822,629

G

microRNA 130b

CTD Direct Evidence: marker/mechanism

NCBI chr11:83,880,163...83,880,244
Ensembl chr11:83,880,163...83,880,244

G

microRNA 132

CTD Direct Evidence: marker/mechanism

NCBI chr10:60,023,696...60,023,796
Ensembl chr10:60,023,696...60,023,796

G

microRNA 141

CTD Direct Evidence: marker/mechanism

PMID:22363424 PMID:28545106

NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332

G

microRNA 142

CTD Direct Evidence: marker/mechanism

NCBI chr10:72,557,864...72,557,950
Ensembl chr10:72,557,857...72,557,967

G

microRNA 143

CTD Direct Evidence: marker/mechanism

NCBI chr18:55,101,006...55,101,110
Ensembl chr18:55,101,006...55,101,110

G

microRNA 148a

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr 4:80,333,762...80,333,858
Ensembl chr 4:80,333,762...80,333,858

G

microRNA 150

CTD Direct Evidence: marker/mechanism

NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108

G

microRNA 151b

CTD Direct Evidence: marker/mechanism

NCBI chr 7:105,172,377...105,172,496
Ensembl chr 7:105,172,377...105,172,496

G

microRNA 152

CTD Direct Evidence: marker/mechanism

NCBI chr10:81,832,936...81,833,020
Ensembl chr10:81,832,936...81,833,020

G

microRNA 155

treatment

RGD

PMID:29420849 PMID:26867493 PMID:27673475

RGD:21409750, RGD:25671474, RGD:25671463

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 17

CTD Direct Evidence: marker/mechanism

NCBI chr15:92,180,629...92,180,712
Ensembl chr15:92,180,629...92,180,712

G

microRNA 181c

CTD Direct Evidence: marker/mechanism

NCBI chr19:23,983,523...23,983,628
Ensembl chr19:23,983,523...23,983,628

G

microRNA 188

CTD Direct Evidence: marker/mechanism

NCBI chr X:15,247,715...15,247,794
Ensembl chr X:15,247,715...15,247,794

G

microRNA 18a

CTD Direct Evidence: marker/mechanism

NCBI chr15:92,180,765...92,180,860
Ensembl chr15:92,180,765...92,180,860

G

microRNA 191

CTD Direct Evidence: marker/mechanism

NCBI chr 8:109,264,098...109,264,188

G

microRNA 192

CTD Direct Evidence: marker/mechanism

PMID:22045675 PMID:25359176 PMID:28483554 PMID:28545106

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

microRNA 193a

CTD Direct Evidence: marker/mechanism

NCBI chr10:64,672,343...64,672,454
Ensembl chr10:64,672,343...64,672,454

G

microRNA 193b

CTD Direct Evidence: marker/mechanism

NCBI chr10:1,317,742...1,317,824
Ensembl chr10:1,317,742...1,317,824

G

microRNA 194-1

CTD Direct Evidence: marker/mechanism

NCBI chr13:96,851,166...96,851,248
Ensembl chr13:96,851,166...96,851,248

G

microRNA 19a

CTD Direct Evidence: marker/mechanism

NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993

G

microRNA 1b

CTD Direct Evidence: marker/mechanism

NCBI chr 3:167,487,117...167,487,201
Ensembl chr 3:167,487,117...167,487,201

G

microRNA 200c

CTD Direct Evidence: marker/mechanism

NCBI chr 4:157,523,679...157,523,747

G

microRNA 21

CTD Direct Evidence: marker/mechanism

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 210

CTD Direct Evidence: marker/mechanism

NCBI chr 1:196,326,343...196,326,452
Ensembl chr 1:196,326,337...196,326,454

G

microRNA 217

CTD Direct Evidence: marker/mechanism

NCBI chr14:102,531,505...102,531,609
Ensembl chr14:102,531,505...102,531,609

G

microRNA 22

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133

G

microRNA 221

CTD Direct Evidence: marker/mechanism

NCBI chr X:3,429,465...3,429,573
Ensembl chr X:3,429,465...3,429,573

G

microRNA 222

CTD Direct Evidence: marker/mechanism

NCBI chr X:3,428,904...3,429,006
Ensembl chr X:3,428,904...3,429,006

G

microRNA 223

RNA:increased expression:serum,liver

RGD

NCBI chr X:61,141,887...61,141,996
Ensembl chr X:61,141,887...61,141,996

G

microRNA 23a

CTD Direct Evidence: marker/mechanism

NCBI chr19:23,954,997...23,955,071
Ensembl chr19:23,954,997...23,955,071

G

microRNA 23b

CTD Direct Evidence: marker/mechanism

NCBI chr17:1,813,667...1,813,763
Ensembl chr17:1,813,667...1,813,763

G

microRNA 27b

CTD Direct Evidence: marker/mechanism

PMID:25359176 PMID:28545106

NCBI chr17:1,813,427...1,813,523
Ensembl chr17:1,813,426...1,813,529

G

microRNA 29b-2

CTD Direct Evidence: marker/mechanism

NCBI chr13:106,570,371...106,570,451
Ensembl chr13:106,570,367...106,570,456

G

microRNA 301a

CTD Direct Evidence: marker/mechanism

NCBI chr10:71,925,336...71,925,435
Ensembl chr10:71,925,336...71,925,435

G

microRNA 30a

CTD Direct Evidence: marker/mechanism

PMID:22363424 PMID:25359176 PMID:28545106

NCBI chr 9:25,737,600...25,737,670
Ensembl chr 9:25,737,600...25,737,670

G

microRNA 30b

CTD Direct Evidence: marker/mechanism

NCBI chr 7:100,132,589...100,132,675
Ensembl chr 7:100,132,589...100,132,675

G

microRNA 30c-1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:134,349,237...134,349,325
Ensembl chr 5:134,349,237...134,349,325

G

microRNA 320a

CTD Direct Evidence: marker/mechanism

PMID:28545106 PMID:30125006

NCBI chr15:45,516,392...45,516,473
Ensembl chr15:45,516,392...45,516,473

G

microRNA 328

CTD Direct Evidence: marker/mechanism

NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849

G

microRNA 337

CTD Direct Evidence: marker/mechanism

NCBI chr 6:128,538,903...128,538,999
Ensembl chr 6:128,538,902...128,538,998

G

microRNA 342

CTD Direct Evidence: marker/mechanism

NCBI chr 6:127,565,269...127,565,367
Ensembl chr 6:127,565,269...127,565,367

G

microRNA 345

CTD Direct Evidence: marker/mechanism

NCBI chr 6:127,754,027...127,754,122
Ensembl chr 6:127,754,027...127,754,122

G

microRNA 34a

CTD Direct Evidence: marker/mechanism

NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103

G

microRNA 34c

CTD Direct Evidence: marker/mechanism

NCBI chr 8:51,409,726...51,409,802
Ensembl chr 8:51,409,726...51,409,802

G

microRNA 3545

CTD Direct Evidence: therapeutic

NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656

G

microRNA 361

CTD Direct Evidence: marker/mechanism

NCBI chr X:78,246,206...78,246,275
Ensembl chr X:78,246,206...78,246,275

G

microRNA 410

CTD Direct Evidence: marker/mechanism

NCBI chr 6:128,758,358...128,758,433
Ensembl chr 6:128,758,354...128,758,434

G

microRNA 423

CTD Direct Evidence: marker/mechanism

NCBI chr10:61,914,142...61,914,220
Ensembl chr10:61,914,133...61,914,226

G

microRNA 455

CTD Direct Evidence: marker/mechanism

NCBI chr 5:76,689,313...76,689,390
Ensembl chr 5:76,689,313...76,689,390

G

microRNA 484

CTD Direct Evidence: marker/mechanism

NCBI chr10:887,684...887,760
Ensembl chr10:887,684...887,760

G

microRNA 497

CTD Direct Evidence: marker/mechanism

NCBI chr10:54,951,514...54,951,582
Ensembl chr10:54,951,505...54,951,584

G

microRNA 499a

CTD Direct Evidence: marker/mechanism

NCBI chr 3:144,110,469...144,110,533
Ensembl chr 3:144,110,469...144,110,533

G

microRNA 503

CTD Direct Evidence: marker/mechanism

NCBI chr X:132,806,303...132,806,373
Ensembl chr X:132,806,303...132,806,373

G

microRNA 532

CTD Direct Evidence: marker/mechanism

NCBI chr X:15,247,315...15,247,393
Ensembl chr X:15,247,315...15,247,393

G

microRNA 592

CTD Direct Evidence: marker/mechanism

PMID:22363424 PMID:28545106

NCBI chr 4:56,505,280...56,505,375
Ensembl chr 4:56,505,280...56,505,375

G

microRNA 764

CTD Direct Evidence: marker/mechanism

NCBI chr X:110,678,597...110,678,704
Ensembl chr X:110,678,597...110,678,704

G

microRNA 877

CTD Direct Evidence: marker/mechanism

NCBI chr20:2,811,476...2,811,560
Ensembl chr20:2,811,476...2,811,560

G

microRNA 93

CTD Direct Evidence: marker/mechanism

NCBI chr12:17,043,135...17,043,221
Ensembl chr12:17,043,135...17,043,221

G

microRNA 99a

CTD Direct Evidence: marker/mechanism

NCBI chr11:16,200,443...16,200,523
Ensembl chr11:16,200,443...16,200,523

G

microRNA let-7b

CTD Direct Evidence: marker/mechanism

PMID:28545106 PMID:30125006

NCBI chr 7:116,804,186...116,804,270
Ensembl chr 7:116,804,186...116,804,270

G

microRNA let-7c-1

CTD Direct Evidence: marker/mechanism

NCBI chr11:16,201,163...16,201,256
Ensembl chr11:16,201,158...16,201,265

G

microRNA let-7d

CTD Direct Evidence: marker/mechanism

NCBI chr17:16,115,893...16,115,990
Ensembl chr17:16,115,893...16,115,990

G

microRNA let-7g

CTD Direct Evidence: marker/mechanism

NCBI chr 8:106,822,293...106,822,380
Ensembl chr 8:106,822,280...106,822,388

G

microRNA let-7i

CTD Direct Evidence: marker/mechanism

NCBI chr 7:58,642,485...58,642,569
Ensembl chr 7:58,642,480...58,642,571

G

matrix metallopeptidase 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

CTD Direct Evidence: marker/mechanism

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

macrophage stimulating 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:108,767,886...108,773,425
Ensembl chr 8:108,768,839...108,773,416

G

macrophage stimulating 1 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 8:108,596,100...108,611,441
Ensembl chr 8:108,597,299...108,612,455

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

mRNA:decreased expression:blood

RGD

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

methylenetetrahydrofolate reductase

treatment

CTD Direct Evidence: marker/mechanism
associated with precursor lymphoblastic lymphoma/leukemia; DNA:SNP: :677C>T(human)

CTD
RGD

PMID:18551038 PMID:19648163 PMID:30545275

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

myotrophin

CTD Direct Evidence: marker/mechanism

NCBI chr 4:64,159,273...64,186,686
Ensembl chr 4:64,157,641...64,186,724

G

murinoglobulin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 4:155,164,061...155,236,894
Ensembl chr 4:155,164,011...155,236,475

G

MYD88, innate immune signal transduction adaptor

ameliorates

RGD

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

N-acetyltransferase 2

treatment

associated with Tuberculosis;DNA:haplotype: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:11915035 PMID:16799928 PMID:17950035 PMID:25693865 PMID:18023090

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

NADH:ubiquinone oxidoreductase core subunit S3

CTD Direct Evidence: marker/mechanism

NCBI chr 3:76,876,646...76,883,824
Ensembl chr 3:76,876,646...76,883,824

G

nuclear factor of activated T-cells 4

CTD Direct Evidence: therapeutic

NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610

G

NFE2 like bZIP transcription factor 2

treatment

induced by methotrexate (CHEBI:44185), treated by ferulic acid (CHEBI:17620)
CTD Direct Evidence: therapeutic

CTD
RGD

PMID:22491424 PMID:22627062 PMID:24813929 PMID:26958860 PMID:30215777 More...

RGD:6893370, RGD:21201308, RGD:21201305, RGD:21201283, RGD:21201280, RGD:15090820

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

treatment
susceptibility

associated with tuberculosis ;DNA:SNPs,haplotypes: 3'utr,5'utr: (rs78872571,rs4647992) (human)

RGD

PMID:29091898 PMID:31490979

RGD:15090820, RGD:40902984

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nuclear transcription factor, X-box binding-like 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498

G

NME/NM23 nucleoside diphosphate kinase 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:78,898,097...78,903,514
Ensembl chr10:78,897,770...78,903,538
Ensembl chr20:78,897,770...78,903,538

G

notch receptor 1

CTD Direct Evidence: therapeutic

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

NADPH oxidase 4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

NAD(P)H quinone dehydrogenase 1

treatment

RGD

PMID:28522909 PMID:29091898 PMID:28472605

RGD:13439737, RGD:15090820, RGD:13439739

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 2

CTD Direct Evidence: therapeutic

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group D, member 1

treatment

RGD

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group H, member 3

CTD Direct Evidence: therapeutic

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

treatment
severity

CTD Direct Evidence: marker/mechanism
mRNA:decreased expression:liver (rat)
protein:decreased expression:liver (rat)

CTD
RGD

PMID:12875239 PMID:29091898 PMID:28827769 PMID:30068870 PMID:22711662 More...

RGD:15090820, RGD:15045609, RGD:15042870, RGD:14701036, RGD:14701035

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

susceptibility

CTD Direct Evidence: marker/mechanism|therapeutic
associated with tuberculosis ;DNA:SNP,haplotypes:promoter: (rs3814055) (human)

CTD
RGD

PMID:19797606 PMID:28058446 PMID:31490979

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:14742670 PMID:25656644 PMID:28058446

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 2, group F, member 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031

G

nuclear receptor subfamily 5, group A, member 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

neuronal regeneration related protein

CTD Direct Evidence: marker/mechanism

NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591

G

netrin 1

CTD Direct Evidence: therapeutic

NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326

G

NUS1 dehydrodolichyl diphosphate synthase subunit

CTD Direct Evidence: therapeutic

NCBI chr20:31,811,817...31,838,562
Ensembl chr20:31,811,817...31,838,561

G

alpha-2u globulin PGCL4

CTD Direct Evidence: marker/mechanism

NCBI chr 5:74,842,316...74,845,858
Ensembl chr 5:74,842,316...74,845,757

G

OCIA domain containing 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:34,897,851...34,915,291
Ensembl chr14:34,897,847...34,915,286

G

oxoglutarate dehydrogenase

CTD Direct Evidence: marker/mechanism

NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479

G

olfactory receptor 59

CTD Direct Evidence: marker/mechanism

NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179

G

prolyl 4-hydroxylase subunit beta

CTD Direct Evidence: marker/mechanism

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

phenylalanine hydroxylase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

poly(A) specific ribonuclease subunit PAN2

CTD Direct Evidence: marker/mechanism

NCBI chr 7:729,146...747,744
Ensembl chr 7:729,562...747,744

G

Pannexin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:11,851,176...11,889,774
Ensembl chr 8:11,850,730...11,889,774

G

Parkinsonism associated deglycase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970

G

pyruvate carboxylase

CTD Direct Evidence: marker/mechanism

NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380

G

procollagen C-endopeptidase enhancer

CTD Direct Evidence: marker/mechanism

NCBI chr12:19,084,191...19,090,508
Ensembl chr12:19,084,210...19,090,508

G

phosphate cytidylyltransferase 1A, choline

CTD Direct Evidence: marker/mechanism

NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357

G

pyruvate dehydrogenase kinase 4

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:21182459 PMID:31809757

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

PDZ and LIM domain 5

CTD Direct Evidence: marker/mechanism

NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275

G

peroxisomal biogenesis factor 11 alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 1:133,680,091...133,687,172
Ensembl chr 1:133,680,091...133,687,172

G

phosphoglucomutase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728

G

plasminogen activator, tissue type

CTD Direct Evidence: marker/mechanism

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

plasminogen

CTD Direct Evidence: marker/mechanism

NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786

G

plastin 3

CTD Direct Evidence: marker/mechanism

NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891

G

purine nucleoside phosphorylase

CTD Direct Evidence: marker/mechanism

NCBI chr15:24,170,607...24,178,269
Ensembl chr15:24,170,602...24,203,986

G

proline-rich nuclear receptor coactivator 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:47,647,070...47,657,832
Ensembl chr 5:47,647,071...47,650,161

G

DNA polymerase gamma, catalytic subunit

susceptibility
no_association

CTD Direct Evidence: marker/mechanism
DNA:missense mutation:cds:p.W748S, p.E1143G (2243G>C, 3428A>G) (human)
DNA:missense mutations:cds:p.Q1236H, p.E1143G (33708G>T, 3428A>G) (human)

CTD
RGD

PMID:18208989 PMID:20138553 PMID:25065347 PMID:30255931

RGD:15039302, RGD:15039297

NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567

G

RNA polymerase II subunit G

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,689,160...205,692,537
Ensembl chr 1:205,689,160...205,692,686

G

paraoxonase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

LPS-induced acute liver damage
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:24385052 PMID:38181850 PMID:21262334

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

mRNA, protein:decreased expression:liver

RGD

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase targeting COQ7

CTD Direct Evidence: marker/mechanism

NCBI chr12:34,249,963...34,288,339
Ensembl chr12:34,249,977...34,288,339

G

protein kinase AMP-activated catalytic subunit alpha 1

treatment

RGD

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

protein kinase C, delta

CTD Direct Evidence: therapeutic

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

protein kinase, DNA-activated, catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952

G

pancreas associated transcription factor 1a

CTD Direct Evidence: therapeutic

NCBI chr17:82,051,281...82,053,135
Ensembl chr17:82,051,281...82,053,135

G

prostaglandin E synthase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:15,690,501...15,697,688
Ensembl chr 3:15,690,501...15,697,688

G

prostaglandin-endoperoxide synthase 2

treatment

CTD Direct Evidence: therapeutic

CTD
RGD

PMID:11743745 PMID:29091898

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

pumilio RNA-binding family member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:142,836,933...142,954,331
Ensembl chr 5:142,837,127...142,954,039

G

glycogen phosphorylase L

CTD Direct Evidence: marker/mechanism
protein:increased expression:serum (rat)

CTD
RGD

PMID:25231249 PMID:25336395

NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310

G

RAS p21 protein activator 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:15,857,704...15,940,757
Ensembl chr 2:15,857,980...15,940,854

G

retinol binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743

G

retinol dehydrogenase 13

CTD Direct Evidence: marker/mechanism

NCBI chr 1:69,373,014...69,401,454
Ensembl chr 1:69,373,113...69,400,908

G

receptor accessory protein 5

CTD Direct Evidence: marker/mechanism

NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509

G

regucalcin

CTD Direct Evidence: marker/mechanism

NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450

G

receptor-interacting serine-threonine kinase 3

CTD Direct Evidence: therapeutic
protein:increased expression:liver (mouse)

CTD
RGD

PMID:26769846 PMID:28205631

NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121

G

RT1 class II, locus Ba

susceptibility

DNA:polymorphism: :HLA-DQA1*0102(human)
associated with tuberculosis;DNA:polymorphism: :HLA-DQA1*0102(human)

RGD

PMID:20639878 PMID:12359646

RGD:14398844, RGD:14401573

NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744

G

RT1 class II, locus Bb

susceptibility

CTD Direct Evidence: marker/mechanism
DNA:polymorphism: :HLA-DQB1*05(human)
DNA:polymorphism, haplotype

CTD
RGD

PMID:21570397 PMID:25250564 PMID:26959717

RGD:36174016, RGD:11573514

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class I, locus CE16

CTD Direct Evidence: marker/mechanism

PMID:21570397 PMID:28043905

NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563

G

RT1 class II, locus Db1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

G

S100 calcium binding protein A11

CTD Direct Evidence: marker/mechanism

NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044

G

scavenger receptor class B, member 1

mRNA:increased expression:liver (rat)

RGD

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

selenium binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594

G

semaphorin 3A

CTD Direct Evidence: therapeutic

NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432

G

semaphorin 4A

CTD Direct Evidence: marker/mechanism

NCBI chr 2:173,896,432...173,917,903
Ensembl chr 2:173,896,439...173,914,442

G

SUMO specific peptidase 2

CTD Direct Evidence: therapeutic

NCBI chr11:78,981,429...79,018,274
Ensembl chr11:78,981,432...79,018,238

G

serpin family A member 1

susceptibility

protein:decreased expression:plasma
DNA:missense mutation:cds:p.E264V(human)

RGD

PMID:11140575 PMID:20170533

RGD:1643168, RGD:14695048

NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339

G

serpin family A member 6

CTD Direct Evidence: marker/mechanism

NCBI chr 6:122,780,040...122,790,274
Ensembl chr 6:122,780,043...122,790,349

G

serpin family E member 1

treatment

associated with precursor lymphoblastic lymphoma/leukemia;DNA:SNPs: :DNA:SNPs: :677C>T, 1298A>C(human)

RGD

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

serpin family G member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:69,842,726...69,852,583
Ensembl chr 3:69,842,739...69,852,034

G

sestrin 2

CTD Direct Evidence: therapeutic

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

SAGA complex associated factor 29

CTD Direct Evidence: marker/mechanism

NCBI chr 1:181,238,458...181,271,931
Ensembl chr 1:181,238,468...181,274,781

G

SHC adaptor protein 1

CTD Direct Evidence: marker/mechanism

PMID:25231249 PMID:32659284

NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536

G

solute carrier family 10 member 1

mRNA:decreased expression:liver (rat)

RGD

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 10, member 7

CTD Direct Evidence: marker/mechanism

NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464

G

solute carrier family 13 member 4

CTD Direct Evidence: marker/mechanism

NCBI chr 4:63,943,369...63,988,852
Ensembl chr 4:63,943,395...63,988,857

G

solute carrier family 22 member 8

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 25 member 29

CTD Direct Evidence: marker/mechanism

NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940

G

solute carrier family 7 member 5

treatment

RGD

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

secretory leukocyte peptidase inhibitor

CTD Direct Evidence: marker/mechanism

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

sorting nexin 18

CTD Direct Evidence: marker/mechanism

NCBI chr 2:45,232,325...45,258,345
Ensembl chr 2:45,232,325...45,258,345

G

superoxide dismutase 1

CTD Direct Evidence: marker/mechanism

PMID:20623750 PMID:27349771

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

treatment
severity
susceptibility

CTD Direct Evidence: marker/mechanism
associated with acute lymphoblastic leukemia;DNA:SNP: :(rs4880)(human)
DNA:SNP:cds:p.Val16Ala(human)

CTD
RGD

PMID:25226513 PMID:27019981 PMID:19647030 PMID:19332662 PMID:20578157

RGD:11060605, RGD:26923961, RGD:26923959, RGD:26923957

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

superoxide dismutase 3

CTD Direct Evidence: therapeutic

NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990

G

sorbitol dehydrogenase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133

G

sortilin related receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513

G

spindlin family member 2A

CTD Direct Evidence: marker/mechanism

NCBI chr X:17,511,018...17,513,001
Ensembl chr X:17,511,022...17,513,001

G

secreted phosphoprotein 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

signal recognition particle 72

CTD Direct Evidence: marker/mechanism

NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729

G

signal transducer and activator of transcription 3

CTD Direct Evidence: therapeutic

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 4

severity

protein:increased phosphorylation:liver, inflammatory cell (mouse)
mRNA:increased expression:liver, macrophage (mouse)

RGD

PMID:24731448 PMID:23876342

RGD:25671417, RGD:25671422

NCBI chr 9:49,472,660...49,588,540
Ensembl chr 9:49,419,340...49,588,540

G

stimulator of interferon response cGAMP interactor 1

CTD Direct Evidence: therapeutic

NCBI chr18:27,332,119...27,338,371
Ensembl chr18:27,332,119...27,338,335

G

sulfotransferase family 1C member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:7,221,580...7,266,991
Ensembl chr 9:7,221,578...7,267,030

G

sulfotransferase family 1E member 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

sulfotransferase family 2B member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295

G

sulfite oxidase

CTD Direct Evidence: marker/mechanism

NCBI chr 7:1,103,149...1,107,156
Ensembl chr 7:1,103,151...1,107,038

G

transgelin 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972

G

transaldolase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974

G

thromboxane A2 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176

G

tectonic family member 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:34,309,795...34,347,190
Ensembl chr12:34,309,897...34,342,267

G

transferrin

CTD Direct Evidence: marker/mechanism

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transforming growth factor, beta 1

treatment

RGD

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777

G

thrombospondin 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

thrombopoietin

CTD Direct Evidence: therapeutic

Ensembl chr11:80,182,820...80,188,167

G

toll-like receptor 4

disease_progression

RGD

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

toll-like receptor 5

CTD Direct Evidence: marker/mechanism

NCBI chr13:94,634,778...94,658,992
Ensembl chr13:94,634,801...94,657,738

G

toll-like receptor 9

severity
treatment

protein:increased expression: blood, neutrophil (human)

RGD

PMID:26457748 PMID:19164858 PMID:23509352

RGD:18337465, RGD:18337476, RGD:18337473

NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796

G

transmembrane p24 trafficking protein 7

CTD Direct Evidence: marker/mechanism

NCBI chr18:39,318,564...39,325,640
Ensembl chr18:39,297,351...39,325,640

G

transmembrane protein 117

CTD Direct Evidence: marker/mechanism

NCBI chr 7:125,757,591...126,219,692
Ensembl chr 7:125,757,591...126,219,690

G

transmembrane protein 164

CTD Direct Evidence: marker/mechanism

NCBI chr X:106,288,019...106,448,642
Ensembl chr X:106,289,371...106,448,640

G

transmembrane protein 38B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:68,460,304...68,496,026
Ensembl chr 5:68,460,304...68,496,025

G

tumor necrosis factor

treatment
severity

IDA
ISO
IEP
IMP

CTD Direct Evidence: marker/mechanism|therapeutic
protein:increased expression:serum (rat)

CTD
RGD

PMID:7532385 PMID:9696492 PMID:17709330 PMID:19638433 PMID:20623750 More...

RGD:10450531, RGD:15090820, RGD:15036799, RGD:14995485, RGD:14995437, RGD:14995435, RGD:14995432, RGD:14995429, RGD:14975281, RGD:14696804

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily M, member 2

RGD

NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181

G

transthyretin

CTD Direct Evidence: marker/mechanism

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008

G

tubulin, alpha 1A

CTD Direct Evidence: marker/mechanism

NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, beta 4B class IVb

CTD Direct Evidence: marker/mechanism

NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296

G

ubiquitin-like modifier activating enzyme 5

CTD Direct Evidence: marker/mechanism

NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894

G

UDP glucuronosyltransferase family 1 member A1

susceptibility

DNA:SNP:exon (rs4148323)(human)

RGD

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

CTD Direct Evidence: marker/mechanism

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

unc-93 homolog B1, TLR signaling regulator

CTD Direct Evidence: marker/mechanism

NCBI chr 1:201,167,388...201,178,343
Ensembl chr 1:201,152,693...201,178,338

G

ubiquitin specific peptidase 5

CTD Direct Evidence: marker/mechanism

NCBI chr 4:157,619,663...157,634,681
Ensembl chr 4:157,619,643...157,634,711

G

integral membrane transport protein UST5r

CTD Direct Evidence: marker/mechanism

NCBI chr 1:205,210,558...205,286,868
Ensembl chr 1:205,211,034...205,286,718

G

vascular endothelial growth factor A

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:25231249 PMID:17784864

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

CTD Direct Evidence: marker/mechanism

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

von Willebrand factor

protein:increased expression:liver:
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:28527913 PMID:7531171

NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539

G

WASP like actin nucleation promoting factor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:53,083,536...53,132,061
Ensembl chr 4:53,083,536...53,132,022

G

X-ray repair cross complementing 1

susceptibility

DNA:haploinsufficiency: : (mouse)

RGD

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

G

xylulokinase

CTD Direct Evidence: marker/mechanism

NCBI chr 8:119,093,466...119,128,858
Ensembl chr 8:119,096,029...119,128,848

G

zinc finger DHHC-type palmitoyltransferase 23

CTD Direct Evidence: marker/mechanism

NCBI chr11:56,718,702...56,735,063
Ensembl chr11:56,718,826...56,734,194

drug allergy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

angiotensin I converting enzyme

CTD Direct Evidence: marker/mechanism

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

adenosine A1 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adenosine A2a receptor

CTD Direct Evidence: marker/mechanism

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

C-C motif chemokine ligand 11

CTD Direct Evidence: marker/mechanism

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 24

CTD Direct Evidence: marker/mechanism

NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893

G

cysteinyl leukotriene receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121

G

cysteinyl leukotriene receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr15:48,189,476...48,228,750
Ensembl chr15:48,189,073...48,304,136

G

Fas ligand

CTD Direct Evidence: marker/mechanism

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

Fc epsilon receptor Ia

CTD Direct Evidence: marker/mechanism

PMID:17125826 PMID:20485159

NCBI chr13:85,686,099...85,692,394
Ensembl chr13:85,686,092...85,692,351

G

Fc epsilon receptor Ig

CTD Direct Evidence: marker/mechanism

PMID:18534082 PMID:18595682

NCBI chr13:83,649,447...83,654,248
Ensembl chr13:83,649,449...83,671,443

G

glutathione S-transferase mu 1

susceptibility

DNA:deletion: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20485159 PMID:11007341

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

susceptibility

associated with Acquired Immunodeficiency Syndrome;DNA:polymorphism:exon:A>G313 (rs1695) (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20485159 PMID:16297214

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

susceptibility

DNA:deletion: :

RGD

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

granzyme B

CTD Direct Evidence: marker/mechanism

NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814

G

histamine N-methyltransferase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012

G

heat shock protein family A (Hsp70) member 1A

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1 like

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

interleukin 10

CTD Direct Evidence: marker/mechanism

PMID:19222424 PMID:20485159

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

CTD Direct Evidence: marker/mechanism

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 2

RGD

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 4

CTD Direct Evidence: marker/mechanism

PMID:15867870 PMID:20485159

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 4 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980

G

leukotriene C4 synthase

CTD Direct Evidence: marker/mechanism

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

motilin

CTD Direct Evidence: marker/mechanism

NCBI chr20:5,304,249...5,308,948
Ensembl chr20:5,304,249...5,308,948

G

membrane spanning 4-domains A2

CTD Direct Evidence: marker/mechanism

PMID:16839402 PMID:18534082 PMID:20485159

NCBI chr 1:208,440,179...208,448,716
Ensembl chr 1:208,440,361...208,448,310

G

N-acetyltransferase 2

CTD Direct Evidence: marker/mechanism

PMID:20485159 PMID:20602614 PMID:21572414

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

NLR family, pyrin domain containing 3

CTD Direct Evidence: marker/mechanism

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

periostin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099

G

prostaglandin E receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434

G

prostaglandin-endoperoxide synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

RT1 class II, locus Db1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

G

tachykinin, precursor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

thromboxane A synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

PMID:11294926 PMID:20485159

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 10b

CTD Direct Evidence: marker/mechanism

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

Drug Eruptions

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 5-lipoxygenase

CTD Direct Evidence: marker/mechanism

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

apolipoprotein A1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein C2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476

G

apolipoprotein C3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

brain-derived neurotrophic factor

mRNA:increased expression:lymph node, ear:

RGD

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

complement C4B

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

cytochrome P450, family 1, subfamily a, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily C, polypeptide 6

susceptibility
treatment

DNA:SNP: :Rs4244285(human)
associated with tuberculosis; DNA.polymorphism, haplotype:cds:p.W212X (human)

RGD

PMID:23551241 PMID:20941486

RGD:11352742, RGD:124713543

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily e, polypeptide 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

Fc epsilon receptor Ia

CTD Direct Evidence: marker/mechanism

NCBI chr13:85,686,099...85,692,394
Ensembl chr13:85,686,092...85,692,351

G

interferon gamma

CTD Direct Evidence: marker/mechanism

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 17A

CTD Direct Evidence: marker/mechanism

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 18

CTD Direct Evidence: marker/mechanism

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

kininogen 1

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:1371395 PMID:3034372

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

myeloperoxidase

CTD Direct Evidence: marker/mechanism

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

methylenetetrahydrofolate reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

RELA proto-oncogene, NF-kB subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RT1 class II, locus Ba

susceptibility

DNA:polymorphisms:exon:

RGD

NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744

G

RT1 class II, locus Bb

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class II, locus Hb, pseudogene 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618

G

tachykinin, precursor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transthyretin

CTD Direct Evidence: marker/mechanism

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008

Drug Hypersensitivity Syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

complement C1q A chain

CTD Direct Evidence: marker/mechanism

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534

G

complement C1q B chain

CTD Direct Evidence: marker/mechanism

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407

G

complement C1q C chain

CTD Direct Evidence: marker/mechanism

NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017

G

complement factor H-related 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:51,395,583...51,410,571
Ensembl chr13:51,369,211...51,410,592

G

C-reactive protein

CTD Direct Evidence: marker/mechanism

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

heat shock protein family A (Hsp70) member 1 like

DNA:polymorphism, haplotype: :p.M493T (human)

RGD

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

interleukin 1 beta

DNA:SNP:promoter:-511C>T (rs 16944) (human)

RGD

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

DNA:SNP:intron:rs2234663 (human)

RGD

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

lipopolysaccharide binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

leucine-rich alpha-2-glycoprotein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813

G

orosomucoid 1

CTD Direct Evidence: marker/mechanism

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

von Willebrand factor

CTD Direct Evidence: marker/mechanism

NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539

Drug-Induced Dyskinesia

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

RGD

PMID:7740056 PMID:6445277

RGD:1598524, RGD:10047091

NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835

G

calcium voltage-gated channel subunit alpha1 D

RGD

NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215

G

catalase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholecystokinin

CTD Direct Evidence: therapeutic

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

catechol-O-methyltransferase

RGD

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cytochrome P450, family 2, subfamily d, polypeptide 4

RGD

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

drebrin 1

levodopainduced; protein:increased expression:striatum:

RGD

NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984

G

dopa decarboxylase

associated with Parkinson Disease; protein:decreased expression:striatum (rat)

RGD

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

dopamine receptor D1

CTD Direct Evidence: marker/mechanism

PMID:7845605 PMID:10858612 PMID:16982285 PMID:19520364

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:7845605 PMID:10534246 PMID:14629710 PMID:18707801

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

CTD Direct Evidence: marker/mechanism

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

early growth response 1

RGD

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

FosB proto-oncogene, AP-1 transcription factor subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

glutamate decarboxylase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

GTP cyclohydrolase 1

CTD Direct Evidence: therapeutic

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

glial cell derived neurotrophic factor

CTD Direct Evidence: therapeutic

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

glutamate-ammonia ligase

RGD

NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108

G

G protein-coupled receptor kinase 6

associated with Parkinson Disease

RGD

NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644

G

glycogen synthase kinase 3 beta

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

homer scaffold protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

5-hydroxytryptamine receptor 1A

RGD

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

microtubule-associated protein tau

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

mechanistic target of rapamycin kinase

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

prodynorphin

treatment
severity

CTD Direct Evidence: marker/mechanism
associated with Parkinsonism
associated with Parkinsonism;protein:increased expression:striatum

CTD
RGD

PMID:9767399 PMID:21737418 PMID:10869049 PMID:17884291 PMID:21737418

RGD:401900134, RGD:401851046, RGD:401850563

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

proenkephalin

treatment
disease_progression

mRNA:increased expression:brain:striatum:
associated with Parkinsonism
associated with Parkinsonism;mRNA:increased expression:striatum
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:9767399 PMID:20456008 PMID:10869049 PMID:26113400

RGD:10003039, RGD:401900134, RGD:401851054

NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775

G

RAS protein-specific guanine nucleotide-releasing factor 1

CTD Direct Evidence: therapeutic

NCBI chr 8:90,445,154...90,574,274
Ensembl chr 8:90,445,154...90,574,269

G

RELA proto-oncogene, NF-kB subunit

protein:increased expression:nucleus, brain

RGD

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

regulator of G-protein signaling 4

treatment

associated with Parkinsonian Disorders

RGD

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

G

regulator of G-protein signaling 9

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:18160641 PMID:24663062

NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892

G

tyrosine hydroxylase

CTD Direct Evidence: therapeutic

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

Drug-Induced Enteropathy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nitric oxide synthase 3

treatment

RGD

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

drug-induced hepatitis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

susceptibility
no_association

DNA:polymorphisms,haplotype:promoter:g.-1774delG,g.-1549G>A(human)
DNA:SNPs:multiple:

RGD

PMID:17502832 PMID:22178260

RGD:14700816, RGD:14700817

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

cytochrome P450, family 2, subfamily e, polypeptide 1

DNA:hypermethylation:promoter

RGD

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023